In addition, miR-31, identified as decreasing in AD patients, has been found to simultaneously reduce APP and BACE1 mRNA levels, leading to significant improvements in memory deficits and cognitive inflexibility. This evidence concerns the gene BACE1 and Alzheimer disease.